GlassScriptPhysician profile
Zoe Woltjer
NPI 1306411897
$5,562.24
in general payments reported to CMS, 2019-2025
37 companies · $1,665 in 2025
The $1,665 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $259 · 2022: $613 · 2023: $1,790 · 2024: $1,235 · 2025: $1,665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,994 · Education: $696.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,994.24 |
| Education | $695.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $727.59 | 2023-2025 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $648.01 | 2021-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Abbvie INC. | $590.51 | 2022-2025 | |
| Janssen Biotech, INC. | $588.98 | 2023-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $369.12 | 2021-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $352.85 | 2025 | |
| Glaxosmithkline, LLC. | $329.46 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $276.38 | 2023-2025 | |
| Pfizer INC. | $174.98 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $171.59 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $138.70 | 2021-2024 | Opsumit, Uptravi |
| Grifols USA, LLC | $127.88 | 2021-2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $104.51 | 2023-2025 | Glassia |
| Baxter Healthcare | $84.81 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Pulmonx Corporation | $84.27 | 2022-2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $72.86 | 2022-2025 | Zepbound, Mounjaro, Taltz |
| Novo Nordisk INC | $64.89 | 2022-2025 | Ozempic, Rybelsus |
| Arcutis Biotherapeutics, INC. | $62.73 | 2023-2025 | Zoryve |
| Ucb, INC. | $56.32 | 2025 | Bimzelx |
| Idorsia Pharmaceuticals US INC | $46.55 | 2022-2024 | Quviviq |
| Mylan Specialty L.P. | $43.21 | 2021-2022 | |
| Exact Sciences Corporation | $39.18 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.34 | 2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $38.12 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $37.64 | 2023-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Leo Pharma INC. | $35.82 | 2024 | Adbry |
| Biogen, INC. | $34.37 | 2021-2022 | |
| Galderma Laboratories, L.P. | $32.90 | 2025 | Nemluvio |
| Astrazeneca Pharmaceuticals LP | $27.13 | 2025 | Breztri |
| Amgen INC. | $26.68 | 2022 | |
| Viatris Specialty LLC | $25.00 | 2025 | Yupelri |
| Philips North America LLC | $21.88 | 2021 | |
| Kyowa Kirin, INC. | $21.18 | 2024 | Crysvita |
| Vertex Pharmaceuticals Incorporated | $20.86 | 2025 | |
| Antares Pharma, INC. | $17.43 | 2024 | Xyosted |
| Eisai INC. | $16.42 | 2021 | |
| Phadia US INC. | $13.09 | 2023 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zoe Woltjer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.